- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03129646
Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa
An Open Label, Phase III, Randomized Controlled, Multicentre Non-Inferiority Trial to Compare Efficacy and Safety of Miltefosine and Paromomycin With SSG and PM Combination for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The 2 treatment regimens to be tested are:
- Arm 1: Paromomycin 20 mg/kg/d IM for 14 days combined with oral miltefosine allometric dosing for 14 days
- Arm 2: Paromomycin 20 mg/kg/d IM for 14 days combined with oral miltefosine allometric dosing for 28 days (recruitment in this arm was discontinued under protocol v4.0 dated 22 Jul 2019)
The reference arm is the current standard treatment for VL:
• Arm 3: Sodium Stibogluconate 20 mg/kg/day IM/IV combined with Paromomycin 15 mg/kg/day IM for 17 days
The target population will be VL patients from 4 to 50 years old in order to cover both paediatric and adult population.
Patients will be hospitalized for 14 days of PM and MF treatment for both arm 1 and arm 2. MF treatment will start at the same time as PM treatment and for arm 2 it will continue on an out-patient basis until completion of the 28 days treatment.
SSG&PM combination therapy will be administered for 17 days according to routine VL treatment guidelines and patients will remain hospitalized for the entire duration of the treatment.
All patients will be asked to return to the hospital for a full assessment on day 28, and for followup visits on day 56 and at six months.
To respond to the objectives, study assessments will be carried out at screening and on days 1, 3, 7, 14, 21, 28, 56 (one-month post-treatment) and 210 (six-month post-treatment). These assessments will include clinical, parasitological, haematological, biochemistry, safety, pharmacokinetic and pharmacodynamics assessments.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Gondar, Ethiopia
- University Hospital of Gondar
-
-
Amhara
-
Ābderafī, Amhara, Ethiopia
- Abdurafi MSF Health Center
-
-
-
-
West Pokot
-
Kapenguria, West Pokot, Kenya, 30601
- Kacheliba Hospital
-
-
-
-
-
Gedaref, Sudan
- Um El Kher Hospital
-
-
Gedaref
-
Doka, Gedaref, Sudan
- El Hassan Centre for Tropical Medicine
-
Gadarif, Gedaref, Sudan
- Tabarak Allah MSF Hospital
-
-
-
-
Karamoja
-
Amudat, Karamoja, Uganda
- Amudat Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with clinical signs and symptoms of VL and confirmatory parasitological microscopic diagnosis
- Patients aged 4 to < 50 years who are able to comply with the study protocol.
- Patients for whom written informed consent has been obtained (if aged 18 years and over) or signed by parents(s) or legal guardian for patients under 18 years of age. In the case of minors, assent from the children also needs to be obtained as per each country regulatory requirements
Exclusion Criteria:
- Patients who are relapse cases
- Patients with Para-Kala azar dermal leishmaniasis grade 3
- Patients who have received any anti-leishmanial drugs in the last 6 months
- Patients with severe malnutrition (for children aged <5 years: weight-for-height WHO reference curves by sex, z score <-3; for children patients 5-18 years: BMI-for-age WHO reference curves by sex, z score < -3; for adults >18 years: BMI < 16)*
- Patients with positive HIV diagnosis
- Patients with previous history of hypersensitivity reaction or known drug class allergy to any of the study treatments
- Patients with previous history of cardiac arrhythmia or with a clinically significant abnormal ECG
- Patients suffering from a concomitant severe infection such as TB, schistosomiasis or any other serious underlying disease (e.g. cardiac, renal, hepatic) or chronic condition which would preclude evaluation of the patient's response to study medication
- Pregnant or lactating women
- Female patients of child bearing age who do not accept to have a pregnancy test done at screening and/or who do not agree to use contraception from treatment period until 5 months after the end of treatment (see section 15.2)
- Patients with haemoglobin < 5g/dl
- Patients with signs of severe VL according to Investigator's judgement, requiring an indication for AmBisome therapy based on the clinical manifestations (such as jaundice, bleeding, edema) and clinically significant abnormalities in the following laboratory parameters: haemoglobin, WBC, platelets, liver enzymes (ALT and AST), total bilirubin and creatinine
- Patients with pre-existing hearing loss based on audiometry at baseline
Patients who cannot comply with the planned scheduled visits and procedures of the study protocol
- Note: for Ethiopia only: Patients with severe malnutrition (for patients 4-18 years: MUAC cut-off based on MUAC-for-height reference table; for patients > 18 years: MUAC < 170 mm)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm 1 - MF/PM 14d
Paromomycin 20 mg/kg/d IM for 14 days combined with oral miltefosine allometric dosing for 14 days
|
Miltefosine 10mg and 50mg capsules
Other Names:
Paromomycin sulfate equiv to 750mg paromomycin / 2ml amp
Other Names:
|
Experimental: Arm 2 - MF 28d/PM 14d
Paromomycin 20 mg/kg/d IM for 14 days combined with oral miltefosine allometric dosing for 28 days
|
Miltefosine 10mg and 50mg capsules
Other Names:
Paromomycin sulfate equiv to 750mg paromomycin / 2ml amp
Other Names:
|
Active Comparator: Arm 3 - SSG/PM 17d
Sodium Stibogluconate 20 mg/kg/day IM/IV combined with Paromomycin 15 mg/kg/day IM for 17 days
|
Paromomycin sulfate equiv to 750mg paromomycin / 2ml amp
Other Names:
Sodium stibogluconate 33% 30 ml inj.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Definitive Cure
Time Frame: 6 months follow-up (Day 210)
|
Cure at 6 months follow up defined as absence of clinical signs and symptoms of VL at D210 and no requirement for rescue treatment during the trial (e.g.
no relapse or initial treatment failure).
|
6 months follow-up (Day 210)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Treatment-Emergent Adverse Events
Time Frame: From Screening to day 210
|
|
From Screening to day 210
|
Initial cure at day 28
Time Frame: Initial cure: day 28; Probable cure: day 56
|
Initial cure: cure at the end of treatment (Day 28), defined as recovery of clinical signs and symptoms; absence of parasites (microscopy) and no rescue treatment administered up to and including Day 28. Probable cure: absence of clinical signs and symptoms of VL at D56 and no prior requirement for rescue medication. |
Initial cure: day 28; Probable cure: day 56
|
Pharmacokinetics of paromomycin and miltefosine
Time Frame: During treatment, at 1 month (day 56) and 6 months (day 210) follow-up
|
Total and partial blood plasma exposure to paromomycin and miltefosine defined as the area under the concentration-time curve
|
During treatment, at 1 month (day 56) and 6 months (day 210) follow-up
|
Pharmacodynamics
Time Frame: From baseline until day 210, and at any suspicion of relapse during the trial.
|
Blood parasite clearance over time (qualitative and quantitative), as measured by qPCR from blood samples
|
From baseline until day 210, and at any suspicion of relapse during the trial.
|
Compliance to miltefosine treatment in an outpatient setting
Time Frame: Day 15 to day 28 miltefosine treatment
|
Compliance to MF treatment in an outpatient setting will be assessed through patients' hospital records history, drug accountability and PK measurements.
|
Day 15 to day 28 miltefosine treatment
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jane Mbui, MD, Kenya Medical Research Institute
- Principal Investigator: Joseph Olobo, MD, Prof, College of Health Sciences, Makerere University, Uganda
- Principal Investigator: Ahmed M Musa, MD, Prof, Institute of Endemic Diseases, Sudan
- Principal Investigator: Rezika Mohammed, MD, University Hospital of Gondar, Ethiopia
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Infections
- Vector Borne Diseases
- Parasitic Diseases
- Protozoan Infections
- Skin Diseases, Parasitic
- Skin Diseases, Infectious
- Euglenozoa Infections
- Leishmaniasis
- Leishmaniasis, Visceral
- Anti-Infective Agents
- Antineoplastic Agents
- Anti-Bacterial Agents
- Antifungal Agents
- Antiprotozoal Agents
- Antiparasitic Agents
- Anthelmintics
- Schistosomicides
- Antiplatyhelmintic Agents
- Miltefosine
- Paromomycin
- Antimony Sodium Gluconate
Other Study ID Numbers
- DNDi-MILT/PM-01-VL
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Visceral Leishmaniasis
-
Drugs for Neglected DiseasesNovartis PharmaceuticalsRecruitingPrimary Visceral LeishmaniasisEthiopia
-
Drugs for Neglected DiseasesNovartis PharmaceuticalsRecruiting
-
Drugs for Neglected DiseasesGilead Sciences; Paladin Labs Inc.Completed
-
Drugs for Neglected DiseasesWellcome Trust grant 212346/Z/18/Z - 21st Century Treatments for Sustainable...CompletedVisceral Leishmaniasis | Cutaneous LeishmaniasesUnited Kingdom
-
Centre Hospitalier Universitaire de NiceCompleted
-
IDRIBill and Melinda Gates FoundationCompletedVisceral Leishmaniasis | Post-kala-azar Dermal LeishmaniasisIndia
-
Centre Hospitalier Universitaire de NiceRecruiting
-
International Centre for Diarrhoeal Disease Research...CompletedVisceral LeishmaniasisBangladesh
-
Aurobindo Pharma LtdAxis Clinicals LimitedCompletedVisceral LeishmaniasisBangladesh, India
-
Drugs for Neglected DiseasesCompletedVisceral LeishmaniasisUganda, Kenya
Clinical Trials on Miltefosine
-
Foundation FaderAB FoundationTerminatedCutaneous LeishmaniasisBolivia
-
Fundacion Nacional de DermatologiaHospital Dermatologico de Jorochito; Ministerio de Salud de Bolivia, Programa... and other collaboratorsCompletedCutaneous Leishmaniasis, AmericanBolivia
-
International Centre for Diarrhoeal Disease Research...Recruiting
-
AB FoundationCompleted
-
Foundation FaderCompletedCutaneous LeishmaniasisBolivia
-
Centro de Investigaciones Bioclínicas de la Fundación...UnknownCutaneous LeihmaniasisBolivia
-
Hospital Universitário Professor Edgard SantosMinistry of Health, Brazil; Conselho Nacional de Desenvolvimento Científico... and other collaboratorsCompletedTreatment of Cutaneous Leishmaniasis in Brazil.Brazil
-
AB FoundationCompleted
-
Medecins Sans Frontieres, NetherlandsUnknownOld World Cutaneous Leishmaniasis
-
Institute of Tropical Medicine, BelgiumUniversity of Gondar; Boru Meda HospitalCompleted